Google
PHVS 株価分析 — PHARVARIS BV (Healthcare >> Biotechnology)
PHVS に関するよくある質問
PHVSのROE（自己資本利益率）は？
PHARVARIS BVのROEは-71.60%です。
PHVSの配当利回りは？
PHARVARIS BVの配当利回りは0.00%です。
PHVSの品質スコア（Quality Score）は？
当社のAIはPHVSの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PHVSは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PHVSはどのセクターに属しますか？
PHARVARIS BVはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
PHVS AI Analysis Summary
Our AI summary for PHVS: PHARVARIS BV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -71.60%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 32.62
Price
-1.26
(-3.72%)
Day Change
|
|
|---|
PHVS, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 32.62 |
| PBV / Sector |
10.02 / 5.20
|
| Earning Per Share | -2.33 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
16.91 M
GREAT
|
| Average 1W Daily Value |
12.04 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:19 |
| Symbol | PHVS |
| Name | PHARVARIS BV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 69.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,367.53 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Grafenauweg 8, Zug, Switzerland, 6300
Phone: 31 712036410
Website: https://pharvaris.com
Employees: 134
Sector: Healthcare >> Biotechnology
Description: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
